Clinical Trials Logo

Clinical Trial Summary

This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102 (biosimilar to bevacizumab) and XELOX in first-line treatment of patients with mCRC.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04856787
Study type Interventional
Source Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Contact Qing Yang, M.D
Phone +86 021-61053363
Email [email protected]
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date May 6, 2021
Completion date November 6, 2024

See also
  Status Clinical Trial Phase
Completed NCT02069704 - Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients Phase 1
Completed NCT01705002 - Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. Phase 1
Completed NCT00594984 - Phase I/II Combination With Irinotecan- Erbitux Phase 1/Phase 2
Recruiting NCT03829462 - Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients Phase 3
Active, not recruiting NCT02649790 - Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Cancer Indications Phase 1/Phase 2
Active, not recruiting NCT03511963 - A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC Phase 3